---
title: "Cingulate raises $5 million net through $5,480,000 unsecured promissory note"
url: "https://aibio.space/news/cingulate-raises-5-million-net-through-5-480-000-unsecured-promissory/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2024-12-23"
section: "Debt Financing"
tickers: "NASDAQ:CING"
source: "https://www.sec.gov/Archives/edgar/data/1862150/000149315224051196/ex99-1.htm"
summary: "The note carries 9% annual interest and matures in 18 months. Cingulate says the money extends its cash runway into the fourth quarter of 2025."
---

By the aibio.space news desk.

Sources

- [Cingulate Inc. 8-K (2024-12-23)](https://www.sec.gov/Archives/edgar/data/1862150/000149315224051196/ex99-1.htm)

[CING](https://aibio.space/companies/cingulate/)

2024-12-23

# Cingulate raises $5 million net through $5,480,000 unsecured promissory note

Tickers [CING](https://aibio.space/companies/cingulate/)

The note carries 9% annual interest and matures in 18 months. Cingulate says the money extends its cash runway into the fourth quarter of 2025.

## Key facts

- **Company**: Cingulate Inc. (NASDAQ: CING)

- **News type**: Debt Financing

- **Primary source**: [Cingulate Inc. 8-K (2024-12-23)](https://www.sec.gov/Archives/edgar/data/1862150/000149315224051196/ex99-1.htm)

*A trading board being updated by hand. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Cingulate Inc. (Nasdaq: [CING](https://aibio.space/companies/cingulate/)) said on December 23, 2024 that it completed a financing with an accredited investor that gave it net proceeds of $5 million.

The deal is a non-convertible, unsecured promissory note with a principal amount of $5,480,000. Non-convertible means the debt cannot be turned into shares. Unsecured means it is not backed by specific company assets. The note accrues interest at 9% per annum and matures 18 months after it was issued.

The Kansas City, Kansas company said it intends to use the net proceeds for working capital and other general corporate purposes. Based on planned spending, Cingulate said the added capital funds its clinical, manufacturing and regulatory work and operating costs into the fourth quarter of 2025.

Cingulate is targeting mid-2025 to file a New Drug Application, the formal request for FDA approval, for CTx-1301.

The note was sold in a private placement under Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D, and has not been registered with the SEC.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

CING

Cingulate Inc.

NASDAQ · United States

Open the starter desk

## More in Debt Financing

Debt Financing

### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Oct 30, 2026

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

Oct 30, 2026

Debt Financing

### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/)

Oct 29, 2026

---
Source page: https://aibio.space/news/cingulate-raises-5-million-net-through-5-480-000-unsecured-promissory/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cingulate raises $5 million net through $5,480,000 unsecured promissory note", 2024-12-23, https://aibio.space/news/cingulate-raises-5-million-net-through-5-480-000-unsecured-promissory/